PharmaPoint: Dermatophytic Onychomycosis (DO) Industry - US Drug Forecast and Market Analysis to 2022 : MarketResearchReports.Biz

MarketResearchReports.Biz announces addition of new report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” to its database


Albany, NY -- (SBWire) -- 07/05/2013 --Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved.

Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.

To check out the Complete table of contents, visit:


Overview of DO, including epidemiology, etiology, general symptoms from infection, and disease management recommendations and guidelines.
Annualized DO market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO market.
Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically new therapies with novel routes of administration.
Analysis of the current and future market competition in the US DO market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Browse All The Report Of This Publisher Visit:

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

Key Findings

Generic therapies are expected to pose as a considerable threat to upcoming topical therapies because of their shorter treatment duration.
The first wave of new pipeline candidates will increase drug treatment rates as physicians begin to opt for more safer options for treatment.
Individual compliance, patient co-morbidities, and insurance payers function as important considerations in assessing the treatment algorithm for every patient.

To Buy The Copy of This Report Visit:

Key Questions Answered in this Report

How big of an impact will topical agents have on the DO market? What do key opinion leaders think of this paradigm shift?
What new product is expected to become the market leader during the forecast period? How will this impact the existing generic therapies?
How will a change in the route of administration change the uptake of drugs in the US market?
What are the primary unmet needs that exist in the market according to key opinion leaders?
What alliance opportunities exist in this market for a company looking to tap into the DO market?

About MarketResearchReports.Biz
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Media Relations Contact

Sheela AK
Business Head
Market Research Reports

View this press release online at: